DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
PRECISION BIOSCIENCES INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Operating Segment | $34.26M | $68.70M | – | – | – | – | 100.0% | -50.1% |
| Therapeutics | – | – | $111.72M | $21.86M | $20.63M | $9.52M | – | – |
| Food | – | – | $3.81M | $2.42M | $1.61M | $1.36M | – | – |
| Operating income | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 | FY2018 | YoY |
|---|---|---|---|---|---|---|---|
| Operating Segment | -$52.15M | -$26.16M | – | – | – | – | +99.3% |
| Therapeutics | – | – | $31.98M | -$49.98M | -$49.43M | -$37.13M | – |
| Food | – | – | -$3.83M | -$5.17M | -$5.38M | -$10.67M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Precision Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.